Bifogade filer
Kurs
+4,64%
Likviditet
86,5 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-02-04 | 07:50 | Bokslutskommuniké 2025 |
2025-10-23 | 07:50 | Kvartalsrapport 2025-Q3 |
2025-07-15 | 07:50 | Kvartalsrapport 2025-Q2 |
2025-05-09 | N/A | X-dag ordinarie utdelning ALIF B 0.75 SEK |
2025-05-08 | N/A | Årsstämma |
2025-04-25 | - | Kvartalsrapport 2025-Q1 |
2025-02-05 | - | Bokslutskommuniké 2024 |
2024-10-23 | - | Kvartalsrapport 2024-Q3 |
2024-07-15 | - | Kvartalsrapport 2024-Q2 |
2024-05-10 | - | X-dag ordinarie utdelning ALIF B 0.50 SEK |
2024-05-08 | - | Årsstämma |
2024-04-24 | - | Kvartalsrapport 2024-Q1 |
2024-02-02 | - | Bokslutskommuniké 2023 |
2023-10-26 | - | Kvartalsrapport 2023-Q3 |
2023-07-14 | - | Kvartalsrapport 2023-Q2 |
2023-05-05 | - | X-dag ordinarie utdelning ALIF B 1.20 SEK |
2023-05-04 | - | Årsstämma |
2023-04-26 | - | Kvartalsrapport 2023-Q1 |
2023-02-02 | - | Bokslutskommuniké 2022 |
2022-10-27 | - | Kvartalsrapport 2022-Q3 |
2022-07-15 | - | Kvartalsrapport 2022-Q2 |
2022-05-06 | - | X-dag ordinarie utdelning ALIF B 2.00 SEK |
2022-05-05 | - | Årsstämma |
2022-04-28 | - | Kvartalsrapport 2022-Q1 |
2022-02-04 | - | Bokslutskommuniké 2021 |
2021-10-22 | - | Kvartalsrapport 2021-Q3 |
2021-07-15 | - | Kvartalsrapport 2021-Q2 |
2021-05-06 | - | X-dag ordinarie utdelning ALIF B 1.50 SEK |
2021-05-05 | - | Årsstämma |
2021-04-28 | - | Kvartalsrapport 2021-Q1 |
2021-02-03 | - | Bokslutskommuniké 2020 |
2020-11-20 | - | X-dag bonusutdelning ALIF B 0.5 |
2020-11-19 | - | Extra Bolagsstämma 2020 |
2020-10-22 | - | Kvartalsrapport 2020-Q3 |
2020-07-17 | - | Kvartalsrapport 2020-Q2 |
2020-05-27 | - | Split ALIF B 1:4 |
2020-05-08 | - | X-dag ordinarie utdelning ALIF B 0.00 SEK |
2020-05-07 | - | Årsstämma |
2020-04-28 | - | Kvartalsrapport 2020-Q1 |
2020-02-06 | - | Bokslutskommuniké 2019 |
2019-11-07 | - | Kvartalsrapport 2019-Q3 |
2019-07-12 | - | Kvartalsrapport 2019-Q2 |
2019-05-10 | - | X-dag ordinarie utdelning ALIF B 2.20 SEK |
2019-05-09 | - | Årsstämma |
2019-05-09 | - | Kvartalsrapport 2019-Q1 |
2019-02-12 | - | Bokslutskommuniké 2018 |
2018-12-20 | - | Extra Bolagsstämma 2018 |
2018-11-07 | - | Kvartalsrapport 2018-Q3 |
2018-07-13 | - | Kvartalsrapport 2018-Q2 |
2018-06-01 | - | X-dag ordinarie utdelning ALIF B 2.20 SEK |
2018-05-31 | - | Årsstämma |
2018-04-27 | - | Kvartalsrapport 2018-Q1 |
2018-02-13 | - | Bokslutskommuniké 2017 |
2017-10-26 | - | Kvartalsrapport 2017-Q3 |
2017-07-17 | - | Kvartalsrapport 2017-Q2 |
2017-05-30 | - | X-dag ordinarie utdelning ALIF B 1.50 SEK |
2017-05-29 | - | Årsstämma |
2017-04-28 | - | Kvartalsrapport 2017-Q1 |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-10-27 | - | Kvartalsrapport 2016-Q3 |
2016-09-02 | - | X-dag ordinarie utdelning ALIF B 0.00 SEK |
2016-09-01 | - | Årsstämma |
2016-07-15 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | Large Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Margin improvement continues, the debt level is reduced, and acquisition activity increases
The margins improved in both business areas in line with our priorities and initiatives. The debt level continued to decrease, and we have achieved our ambition to lower the net debt in relation to EBITDA to below 3.0. AddLife is now ready to gradually increase acquisition activity, and at the beginning of April, the acquisition of Edge Medical was completed.
Fredrik Dalborg, President and CEO
AddLife´s interim report for Q1 2025 is now available online at the company website. The interim report can be downloaded in pdf version. Visit reports-en.add.life/interim-report-q1-2025
FIRST QUARTER
- Net sales increased by 5 percent to SEK 2,702m (2,570). The organic growth, excluding exchange rate changes, was 4 percent and the acquired growth was 1 percent.
- EBITA increased by 18 percent to SEK 343m (291), corresponding to an EBITA margin of 12.7 percent (11.3).
- Profit for the period amounted to SEK 120m (63).
- Earnings per share amounted to SEK 0.98 (0.52). Earnings per share for the last 12 months amounted to SEK 2.53 (0.65)
- Cash flow from operating activities amounted to SEK 240m (97).
- The equity ratio was 41 percent (41).
- Return on working capital (P/WC) amounted to 53 percent (51).
- After the end of the quarter, an acquisition has been completed, Edge Medical Ltd., UK.
Stockholm, April 25, 2025
AddLife AB (publ)
For further information, please contact
Fredrik Dalborg, CEO, fredrik.dalborg@add.life, +46 70 516 09 01
Christina Rubenhag, CFO, christina.rubenhag@add.life, +46 70 546 72 22
Video conference
Investors, analysts and the media are invited to a video conference at which CEO Fredrik Dalborg and CFO Christina Rubenhag will present the interim report. The presentation will be given in English and take about 20 minutes after which there will be an opportunity to ask questions. The meeting will be recorded and made available online.
The video conference will be at 9 a.m. CEST.
If you wish to participate via video conference, please follow this link>>
The presentation is also available on AddLife YouTube >>
AddLife in brief
AddLife is an independent partner in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors in Europe. AddLife has 2,300 employees in about 85 operating subsidiaries. The Group currently has net sales of more than SEK 10 billion. AddLife shares are listed on Nasdaq Stockholm.
This information is information that AddLife is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-25 07:45 CEST.
Attachments
Interim Report Q1 2025